503Pharma Weekly Compounding Pharmacy Roundup

JOIN FREE MEMBERS AREA | COMPLIANCE TRAINING | FORMULA LIBRARY

This Week's Headlines

FDA Leadership

FDA Commissioner Makary Resigns; Kyle Diamantas Named Acting Commissioner

Marty Makary resigned on May 12 after roughly 13 months leading the agency. Kyle Diamantas, previously deputy commissioner for food, is now acting commissioner. The transition lands in the middle of several active compounding workstreams — the 503B GLP-1 bulks proposal, the reopened 503A bulks docket, and PCAC's two-year renewal — meaning the written record (Federal Register notices, current guidance) becomes the most reliable input until new leadership weighs in.

AP News →

Industry Data

APC Opens Dispensing Data Reporting Initiative to Compounding Pharmacies Nationwide

The Alliance for Pharmacy Compounding is recruiting pharmacies for what it's calling a first-of-its-kind compounding dispensing data reporting initiative — an effort to build the first statistically valid national dataset on what 503As actually dispense. APC's framing is straightforward: drugmakers are already lobbying Congress to mandate dispensing reporting directly to FDA, and the profession has been making its case to regulators with anecdotes instead of numbers.

APC →

Shortage

Liraglutide Injection Listed as Current Shortage as of May 12

FDA's drug shortage database currently lists liraglutide injection. Because liraglutide is also one of the three GLP-1s in FDA's May 1 503B bulks proposal, the shortage entry and the bulks-list pathway will get blended together in some trade press — but they operate under different evidentiary standards. A finished-drug shortage may support lawful compounding under the statutory shortage pathways.

FDA Drug Shortage Database →

Shortage Cluster

Sterile Injectables and Diluents Reverified May 8–12

FDA's feed shows current entries across sterile water for injection and irrigation, 0.9% sodium chloride, local anesthetics (lidocaine, bupivacaine, ropivacaine), opioids (morphine, hydromorphone, fentanyl), and sedatives (midazolam, lorazepam, etomidate). Most notable: at least one Hospira/Pfizer bupivacaine-with-epinephrine presentation now lists a December 2028 estimated recovery — long enough to warrant formulary planning conversations with surgery centers, dental groups, and hospital anesthesia customers.

FDA Drug Shortage Database →

Intel Brief

PCAC AGENDA

Seven Peptides on the July 23–24 PCAC Agenda for 503A Bulks List Consideration

FDA's April 16 Federal Register notice scheduled PCAC for July 23–24, 2026 to consider seven peptides for inclusion on the 503A Bulks List: BPC-157, KPV, TB-500, MOTs-C (Day 1), and Emideltide/DSIP, Semax, and Epitalon (Day 2). Both free base and acetate forms are on the agenda for each. An additional five peptides are scheduled for a separate PCAC meeting before the end of February 2027. The public docket is open for comment now; clinical evidence, route-specific safety rationale, and identified patient populations tend to carry more weight than broad access arguments.

FDA Meeting Notice →

API SUPPLY

Pharmaceutical-Grade API May Be the Real Bottleneck if Peptides Move to Category 1

Even with a favorable PCAC vote in July, most of the seven peptides on the agenda don't have pharmaceutical-grade API available at commercial scale today — current supply is largely research-grade, which cannot lawfully be used in compounded preparations. Under cGMP, compounding pharmacies must source pharmaceutical-grade API from FDA-registered facilities. If FDA reclassifies any of these substances into Category 1, API qualification — not regulatory status — will likely govern how quickly compliant product can reach patients. A few API manufacturers are reportedly positioning for the demand, but pharmacies planning peptide programs should be diligencing supplier readiness now, not after PCAC.

Frier Levitt Analysis →

Legislative & Litigation Watch

Where the bills and cases stand. Updated weekly as developments occur.

Federal Legislation

SAFE Drugs Act (H.R. 6509 / S. 3794) — Still in Committee

The House version (H.R. 6509, introduced December 2025) and Senate version (S. 3794, introduced February 2026) would codify a 20-units-per-month cap on "essentially a copy" compounding under 503A, require FDA reporting for pharmacies shipping more than 20 out-of-state prescriptions monthly, and mandate pre-launch and biennial inspections for large-scale outsourcing facilities. NCPA and APC sent a joint opposition letter to Congress on April 27. No new committee activity this week; bill remains with House Energy and Commerce.

Congress.gov →

Federal Oversight

LITIGATION

Strive Specialties v. Eli Lilly & Novo Nordisk — Active in W.D. Tex.

Strive Compounding Pharmacy's federal antitrust suit (filed January 14, 2026 in the Western District of Texas) alleges Lilly and Novo entered exclusive telehealth partnerships — with Ro, Weight Watchers, LifeMD, and others — that barred those platforms from working with compounders. Worth watching as a commercial-channel question for any 503A relying on telehealth referral volume. No new public docket activity this week.

Complaint →

Research Desk

GLP-1 Adjuncts: A Phase 4 Trial Worth Tracking

One trial worth keeping on the desk: NCT07554417, a Phase 4 Rice University/Houston Methodist study evaluating whether a 12-week exercise and individualized nutrition program reduces muscle and bone loss in obese adults using GLP-1 medications including semaglutide.

The study isn't a compounding trial and doesn't speak to compounded peptide or vitamin add-ons directly. Its relevance is adjacent: it tests a non-pharmacologic intervention against one of the clinical concerns frequently raised in discussions of customized GLP-1 regimens. Positive results would narrow some of the rationale for pharmacologic add-ons. Null results would likely sustain demand for individualized approaches — which still need patient-specific clinical documentation.

ClinicalTrials.gov →

CompoundLearn: Training Built for Compounding Pharmacies

CompoundLearn simplifies USP compliance training so your team can stay inspection-ready without the spreadsheets and paper trails. From onboarding new staff to competency testing, CompoundLearn automates the entire training lifecycle — so you can focus on what matters most: patient safety.

• Full access to 25 training modules and 77 lessons covering critical USP 795, 797, and 800 topics

• Role-based assignments — assign and track the right training curriculum to designated persons/pharmacists-in-charge, compounders, and trainers

• Quizzes and Downloadable certificates that prove that your team knows the material

• 23+ Ready-Made Compliance Templates — Downloadable cleaning logs, sampling records, labeling checklists, and more — ready to use out of the box

• Custom Module Creation — Build pharmacy-specific training for your unique protocols and SOPs

• Team & Role Management — Assign training by role (designated person, compounder, technician) and track progress across your entire organization

[Start Now at CompoundLearn →]

✉️ That’s your 503Pharma weekly digest. Our mission is to keep compounding professionals informed, prepared, and ahead of the curve.